REDUCE LAP-HFREF TRIAL

The intended clinical indication of the IASD System II is the reduction of elevated LAP in
patients with symptomatic heart failure with reduced ejection fraction, despite appropriate
medical management. The implant is designed with a center barrel opening that, in the setting
of elevated LAP, allows left to right flow. Since many of the symptoms these patients
experience are believed to be due to elevated LAP, the IASD System II has the potential to
significantly reduce symptoms and improve the quality of life in patients with otherwise
limited treatment options.

The study design is a prospective, non-randomized, single-arm feasibility trial. This study
will implant up to 10 subjects. The population will include heart failure patients with
reduced ejection fraction, and elevated left sided filling pressures, who remain symptomatic
despite GDMT, including optimal doses of recommended pharmaceutical treatments, surgical, and
device intervention(s) (CRT, AICD, reduction of MRI). After analysis of the 1 month results
(including baseline and 1 month Core laboratory echocardiographic and hemodynamic data) of
the first 5 implanted patients, a decision will be made to implant an additional 5 patients,

Inclusion Criteria:

1. Chronic symptomatic Heart Failure (HF) documented by the following:

1. New York Heart Association (NYHA) Class III/ambulatory class IV symptoms
(Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion)
at screening visit, and signs (e.g. any rales post cough, Chest x-ray
demonstrating pulmonary congestion,) within past 12 months; AND

2. One hospital admission for which HF was a major component of the hospitalization
within the 12 months prior to study entry (transient heart failure in the context
of myocardial infarction does not qualify), or one emergency department visit
with IV treatment for HF within the 12 months prior to study entry

2. Ongoing stable GDMT for HF (Class I, and IIa recommendations) according to the 2016
ACC/AHA Guidelines for the management of Heart Failure (with no significant changes
[>100% increase or 50% decrease], excluding diuretic dose changes for a minimum of 3
months prior to screening), which is expected to be maintained without change for 6
months

3. Age ≥ 18 years old

4. Reduced Left ventricular ejection fraction between 20% and 40% as documented by
echocardiography, radio nuclide ventriculography, or MRI within the past 3 months

5. Elevated left atrial pressure with a gradient compared to right atrial pressure (RAP)
documented by:

a. Resting end expiratory PCWP ≥ 18 mmHg, and greater than RAP by ≥ 5 mmHg

6. Subject has been informed of the nature of the study, agrees to its provisions and has
provided written informed consent, as approved by the IRB

7. Subject is willing to comply with clinical investigation procedures and agrees to
return for all required follow-up visits, tests, and exams

Exclusion Criteria:

1. Patients who are not receiving GDMT for specified reasons

2. NT-Pro BNP < 100 pmol/L (if in sinus rhythm), or <300 pmol/L (if in atrial
fibrillation)

3. Myocardial infarction (MI) and/or percutaneous cardiac intervention within past 3
months; CABG in past 3 months, or current indication for coronary revascularization

4. Cardiac Resynchronization Therapy initiated within the past 3 months

5. Automated Implantable Cardioverter Defibrillator (AICD) placed within past 3 months

6. Severe heart failure defined by all of the following:

1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF;

2. Cardiac Index < 2.0 L/min/m2

3. Requiring inotropic infusion (continuous or intermittent) within the past 3
months.

4. Listed on transplant waiting list

7. Ability to perform the 6 minute walk Test >600m

8. Known clinically significant un-revascularized coronary artery disease, defined as:
epi-cardial coronary artery stenosis associated with angina or other evidence of
coronary ischemia.

9. History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or
pulmonary emboli within the past 6 months or recurrent DVT/pulmonary emboli

10. Presence of significant valve disease defined by echocardiography as:

1. Mitral valve regurgitation defined as grade > 2+ MR

2. Tricuspid valve regurgitation defined as grade > 2+ TR;

3. Aortic valve disease defined as ≥ 2+ AR or moderate AS

11. Subject is contraindicated to receive either dual antiplatelet therapy or warfarin
analogue; or has a documented coagulopathy

12. Atrial fibrillation with resting HR > 100 BPM

13. Arterial Oxygen saturation < 95% on room air

14. Significant hepatic impairment defined as 3X upper limit of normal of transaminases,
total bilirubin, or alkaline phosphatase; Hepatic cirrhosis; Hypoalbuminemia

15. Resting RAP > 14 mmHg

16. Right ventricular dysfunction, defined as

1. More than mild RV dysfunction as determined by TTE: OR

2. TAPSE < 1.4 cm: OR

3. RV volume ≥ LV volume on echo estimate; OR

4. Evidence of RV dysfunction defined by echo as an RV fractional area change < 35%

17. Evidence of pulmonary hypertension with PVR ≥4 Woods Units

18. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic
pulmonary disease defined as FEV1 <1L.

19. Currently participating in an investigational drug or device study that may interfere
with the conduct and outcome of this study.

20. Life expectancy less than 12 months for non-cardiovascular reasons

21. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation

22. Known or suspected allergy to nickel

23. Women of child bearing potential

24. Currently requiring dialysis; or e-GFR <25ml/min

25. Systolic blood pressure >170 mmHg despite appropriate medical management

26. Subjects with existing Atrial Septal Defects. Subjects with a Patent Foramen Ovale
(PFO), who have elevated filling pressure despite the PFO are allowed

27. Subjects on immunosuppression or systemic steroid treatment

28. In the opinion of the investigator, the subject is not an appropriate candidate for
the study